Close

PTC Therapeutics (PTCT) Says FDA Denied First Appeal of the Refuse to File Letter

October 17, 2016 8:02 AM EDT Send to a Friend
PTC Therapeutics, Inc. (NASDAQ: PTCT) today provided a regulatory update on Translarna™ (ataluren) for the treatment of nonsense mutation ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login